CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 116 enrolled
Drug / intervention
Antiseptic occlusive dressing groupdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03229824
NCT03229824N/ACompleted

Randomized Controlled Trial to Reduce Surgical Site Infections in Breast Cancer Surgery With Clorhexidine Gluconate Securement Dressing (Tegaderm CHG)

National Institute of Cancerología·interventional·Posted Jul 26, 2017·Updated Nov 13, 2018

In Brief

A clinical study evaluating Antiseptic occlusive dressing group for Breast Cancer. Completed, enrolled 116 participants across 1 site.

Detailed Summary

Surgical site infection (SSI) after breast and axillary surgery occurs more often than for other clean surgical procedures. Infection in the setting of sick woman could delay the adjuvant therapy and result increase morbidity and mortality. Also this increased costs associated with health care.Surgical drains have been noted as a potential source for surgical site infections. The primary aim of the study is to determine if chlorhexidine occlusive dressings applied to the intervention drain sites effectively decreases rates of bacterial colonization in drain fluid and drain tips compared to standard care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesMexico

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 26, 2017
Enrollment StartOct 3, 2016
Primary CompletionApr 30, 2018
Study CompletionMay 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.9 years ago

Interventions

Antiseptic occlusive dressing groupdevice

A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.